Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,183.46 +1.57 (+0.13%)
Official Closing Price Updated: 7:00 PM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product? ↗
The drugmaker badly needs more clinical wins. 
Via The Motley Fool
News headline image
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? ↗
The biotech player could eventually rival big pharma companies. 
Via The Motley Fool
News headline image
2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
Eli Lilly (NYSE:LLY) Fits a Dividend Quality Screen Despite Its Low Yield ↗
Via Chartmill
News headline image
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? ↗
AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations. 
Via The Motley Fool
News headline image
Eli Lilly (LLY) Stock Is Up, What You Need To Know
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after The U.S. Food and Drug Administration ... 
Via StockStory
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration ↗
XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification. 
Via The Motley Fool
Topics ETFs
News headline image
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? ↗
VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility. 
Via The Motley Fool
Topics ETFs
News headline image
Stanley Druckenmiller, Ken Griffin, and Cathie Wood Have at Least 1 Thing in Common: They All Own This Stock ↗
This company is a leader in a high-growth field. 
Via The Motley Fool
News headline image
XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks ↗
XLV's broader diversification and lower fees appeal to cost-conscious investors, while PJP's concentrated pharma bet has outperformed over the past year. 
Via The Motley Fool
Topics ETFs
News headline image
Could Retatrutide Be Worth $10 Billion to Eli Lilly? ↗
The company continues to dominate the weight loss market. 
Via The Motley Fool
Topics Law Enforcement
News headline image
Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved. 
Via MarketBeat
News headline image
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up? ↗
Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits. 
Via MarketBeat
Topics Intellectual Property Lawsuit
News headline image
Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗
The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off. 
Via The Motley Fool
News headline image
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH ↗
IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income. 
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems ↗
Novo Nordisk is dealing with headwinds, but was its name really one of the big problems? 
Via The Motley Fool
News headline image
VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? ↗
VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two. 
Via The Motley Fool
Topics ETFs
News headline image
Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring ↗
Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth. 
Via MarketBeat
Topics Initial Public Offering
News headline image
Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth? ↗
When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk. 
Via The Motley Fool
Topics Economy
News headline image
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall. ↗
Viking and Roche both reported positive results for their weight-loss drugs Tuesday. 
Via Investor's Business Daily
News headline image
2 Cash-Producing Stocks with Exciting Potential and 1 We Brush Off
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem
Via AB Newswire
Topics Animal Testing
News headline image
Eli Lilly Stock Is On Track to Do Something It Hasn't Done Since 2016 ↗
The top healthcare stock has been underperforming the market, and its returns haven't been as impressive as in recent years. 
Via The Motley Fool
News headline image
Meet the Vanguard ETF That Increased Its SpaceX Holding by 39% in 1 Month and Shows No Signs of Slowing Down ↗
The unlocking of SpaceX shares is reshaping the communications sector. 
Via The Motley Fool
Topics ETFs
News headline image
Why Twist Bioscience Stock Skyrocketed This Week ↗
It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Better Buy for Cautious Investors: Eli Lilly vs Costco ↗
These companies may perform well in any market environment. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Automated Labeling Tools Are Modernizing the AI Training Dataset Market ↗
The global AI training dataset market was valued at USD 3.2 billion in 2025 and is projected to reach USD 16.3 billion by 2033, expanding from USD 3.9 bill 
Via Talk Markets
Topics Artificial Intelligence
News headline image
1 Safe-and-Steady Stock Worth Your Attention and 2 We Question
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Ch... 
Via StockStory
Topics Emissions
News headline image
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. ↗
The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.